Lilly's Cyramza misses liver-cancer target

Share this article:

Eli Lilly's gastric cancer drug Cyramza, previously known as ramucirumab, failed to hit its Phase-III targets among liver-cancer patients using the drug as a second-line treatment. The Wall Street Journal reports that although Cyramza patients had more favorable overall survival rates than placebo patients, the differences were not statistically significant.

The drug failed to hit targets in a breast cancer clinical trial last year, but showed promise in Phase-III tests among non-small cell lung cancer patients when used with docetaxel.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.